Braxia Scientific CEO and CMO, Invited to Speak as Experts at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford April 4-6
TORONTO, April 1, 2022 - Braxia Scientific Corp. ("Braxia Scientific", or the "Company"), (CSE: BRAX) (OTC: BRAXF) (FWB: 4960), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce that CEO, Dr. Roger McIntyre and Chief Medical and Scientific Officer, Dr. Josh Rosenblatt have been invited to present at the Ketamine and Related Compounds 2022 International Conference hosted by University of Oxford in Oxford, England. This meeting is one of the largest International Conferences on ketamine research, development, and clinical implementation. Braxia Scientific senior management will present on the following days, London, U.K. time. To access the live online webcasts please visit the conference website, or the links available below: Monday April 4, 2022 16:20 p.m. (London Time) Dr. Roger McIntyre will discuss Ketamine treatment for domain-based outcomes in persons with Treatment Resistant Depression Session abstract available here. 18:00 p.m. (London Time) Dr. Roger McIntyre will participate in a Debate: This House...